St. Jude Children’s Research Hospital offers a 12-month ASHP-accredited specialized (PGY2) Residency in Clinical Pharmacogenomics.
This program prepares residents to excel in implementing pharmacogenomic testing in clinical practice. The Pharmaceutical Department provides unmatched opportunities for clinical use of pharmacogenomics into patient care due to St. Jude’s full integration of an electronic medical record that applies to inpatient and outpatient care, comprehensive translational research programs, highly skilled clinical pharmacy specialist team, and a strong laboratory component of the PGY2 program.
As a resident, you will learn, contribute and participate in a dynamic environment with world experts translating laboratory-based discoveries into comprehensive medication management for multiple disease states.
St. Jude runs an institution-wide program to implement pre-emptive pharmacogenomic testing (PG4KDS). You will assist in directing the PG4KDS program and provide pharmacogenomic consults in the context of a comprehensive approach to pharmaceutical care integrated into the clinical practice areas: general hematology/oncology and bone marrow transplantation. Training will be provided in applied pharmacokinetics, infectious diseases, nutrition support, clinical informatics and advanced pediatric pharmacotherapy. The resident will work with established clinicians on interdisciplinary teams to deliver personalized pharmacotherapy to pediatric patients with catastrophic diseases.
The resident will design safe and effective patient-centered therapeutic regimens and monitoring plans. In addition, you will build pharmacogenomic clinical consults and help develop customized pharmacogenomic clinical decision-support alerts that will alert clinicians of high-risk gene-drug pairs and allow for genetically guided drug dosing. The resident will be expected to write a manuscript for publication and participate in patient education, drug information, quality improvement and medication-outcomes activities.
Residents are highly involved in international efforts to implement pharmacogenomics on a broad scale via participation in the Clinical Pharmacogenetics Implementation Consortium (CPIC). Upon completion of the program, you will have the clinical and leadership skills as well as the necessary experience to manage a clinical pharmacogenomics practice, and to implement pharmacogenomic testing in other health-system settings.
Clinical Pharmacogenomics residents learn, contribute and participate in a dynamic environment that consists of professional and technical personnel in both patient care and pharmaceutical research. Along with direct patient care responsibilities, residents will have the opportunity to gain experience in teaching through lectures, in-services, journal club presentations and precepting pharmacy students. A teaching certificate is offered by the University of Tennessee College of Pharmacy. An independent research project will be carried out during the residency, with a presentation of the findings at a national meeting.
How to Apply
Qualified candidates are strongly encouraged to interview with St. Jude staff at the Professional Placement Service (PPS/CareerPharm) at the ASHP Midyear Clinical Meeting. This year’s meeting will be conducted virtually.
To apply, complete the following materials within PhORCAS:
- Official school transcript(s)
- Letter of intent
- Three (3) letters of reference
Other requirements include:
- Doctor of Pharmacy degree, successful completion of an ASHP-accredited PGY1 Residency, and eligibility for licensure to practice pharmacy in the state of Tennessee
- Completion of an onsite or virtual interview
Application deadline: First Monday of January by 11:59 p.m. CST
Submit residency application materials within PhORCAS to the PGY2 Residency Program Director listed below:
Number of Positions
Kristine R. Crews, PharmD, FCCP, BCPS
Mail Stop 313
Phone: (901) 595-3338